Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sagimet Biosciences Inc SGMT

Healthcare Biotechnology
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor... see more

Recent & Breaking News (NDAQ:SGMT)

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

GlobeNewswire 6 days ago

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire 10 days ago

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

GlobeNewswire November 7, 2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

GlobeNewswire October 29, 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

GlobeNewswire October 16, 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

GlobeNewswire October 11, 2024

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

GlobeNewswire October 1, 2024

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 1, 2024

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

GlobeNewswire September 12, 2024

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire September 4, 2024

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire August 14, 2024

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire August 1, 2024

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 

GlobeNewswire June 10, 2024

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

GlobeNewswire June 6, 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

GlobeNewswire May 16, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire May 15, 2024

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

GlobeNewswire May 7, 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

GlobeNewswire May 6, 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

GlobeNewswire April 22, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

GlobeNewswire March 27, 2024